Alterola Biotech, Inc.: 10-Q filed 2023-11-21

Name: Alterola Biotech, Inc.: 10-Q filed 2023-11-21
Creator: Alterola Biotech, Inc.

What Alterola Biotech, Inc. reported in its quarterly report filed 2023-11-21 (fiscal Q2 2024): 25 published measures, 63 facts as tagged in accession 0001663577-23-000546.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-21
Fiscal period: fiscal Q2 2024
Accession: 0001663577-23-000546 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Alterola Biotech, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	497,208	USD
At 2023-03-31	12,376,963	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit
At 2023-09-30	2,519,231	USD
At 2023-03-31	2,281,416	USD
At 2021-05-28	389,721	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	-2,022,023	USD
At 2023-03-31	10,095,547	USD
At 2022-09-30	10,745,258	USD
At 2022-03-31	11,062,996	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-123,155	USD	92
2023-04-01 to 2023-09-30	-854,887	USD	183
2022-07-01 to 2022-09-30	-375,252	USD	92
2022-04-01 to 2022-09-30	-1,187,941	USD	183

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-04-01 to 2023-09-30	-197,625	USD	183
2022-04-01 to 2022-09-30	-363,213	USD	183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-04-01 to 2023-09-30	75,530	USD	183
2022-04-01 to 2022-09-30	296,947	USD	183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-04-01 to 2023-09-30	35,000	USD	183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-10,431,134	USD
At 2023-03-31	-9,576,247	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-123,155	USD	92
2023-04-01 to 2023-09-30	-716,724	USD	183
2022-07-01 to 2022-09-30	-470,682	USD	92
2022-04-01 to 2022-09-30	-1,283,371	USD	183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	197,208	USD
At 2023-03-31	237,184	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	2,519,231	USD
At 2023-03-31	2,127,103	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	722,124	USD
At 2023-03-31	611,805	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2023-04-01 to 2023-09-30	-44,064	USD	183
2022-04-01 to 2022-09-30	50,280	USD	183

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	123,155	USD	92
2023-04-01 to 2023-09-30	716,724	USD	183
2022-07-01 to 2022-09-30	470,682	USD	92
2022-04-01 to 2022-09-30	1,283,371	USD	183

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2023-09-30	975	USD
At 2023-03-31	986	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	22,614	USD	92
2022-04-01 to 2022-09-30	41,086	USD	183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	778,031,955	shares
At 2023-03-31	807,047,948	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-09-30	9,102	USD
At 2023-03-31	8,890	USD
At 2022-09-30	15,130	USD
At 2022-03-31	63,816	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-09-30	7,581,442	USD
At 2023-03-31	18,927,919	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2023-09-30	246,370	USD
At 2023-03-31	254,864	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2009-10-16 to 2023-09-30	-10,431,134	USD	5098

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	23,644	USD	92
2023-04-01 to 2023-09-30	25,404	USD	183
2022-07-01 to 2022-09-30	24,163	USD	92
2022-04-01 to 2022-09-30	56,821	USD	183

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-123,155	USD	92
2023-04-01 to 2023-09-30	-138,163	USD	183
2022-07-01 to 2022-09-30	-38	USD	92
2022-04-01 to 2022-09-30	-38	USD	183

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	95,469	USD	92
2022-04-01 to 2022-09-30	95,469	USD	183

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-04-01 to 2023-09-30	110,319	USD	183
2022-04-01 to 2022-09-30	24,533	USD	183

Inspect the source

Entity: Alterola Biotech, Inc. / CIK 0001442999
Captured: 2026-09-21T17:19:50.475Z
SEC response SHA-256: 87a3a16f9156f52960516ff7604a147caa80abebfe964591df0bd913491df844

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001442999.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))